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ABSTRACT 
 
Objective: To develop core outcome sets (COS) for studies evaluating interventions for  (1) prevention 
and (2) treatment of PPH, and recommendations on how to report the COS. 
Design: A two-round Delphi survey and face-to-face meeting. 
Population: Health care professionals and women’s representatives. 
Methods: Outcomes were identified from systematic reviews of PPH studies and stakeholder consultation. 
Participants scored each outcome in the Delphi on a Likert scale between 1 (not important) and 9 (critically 
important). Results were discussed at the face-to-face meeting to agree the final COS. Consensus at the 
meeting was defined as  70% of participants scoring the outcome as critically important (7-9). Lectures, 
discussion and voting were used to agree how to report COS outcomes.  
Main outcome measures: outcomes from systematic reviews and consultations. 
 
Results: Both Delphi rounds were completed by 152/205 (74%) participants for prevention and 143/197 
(73%) for treatment. For prevention of PPH, nine core outcomes were selected: blood loss, shock, maternal 
death, use of additional uterotonics, blood transfusion, transfer for higher level of care, women’s sense of 
wellbeing, acceptability and satisfaction with the intervention, breastfeeding and adverse effects. For 
treatment of PPH, 12 core outcomes were selected: blood loss, shock, coagulopathy, hysterectomy, organ 
dysfunction, maternal death, blood transfusion, use of additional haemostatic intervention, transfer for 
higher level of care, women’s sense of wellbeing, acceptability and satisfaction with the intervention, 
breastfeeding and adverse effects. Recommendations were developed on how to report these outcomes 
where possible.   
 
Conclusions: These COS will help standardise outcome reporting in PPH trials.  
 
Funding: British Medical Association (Strutt and Harper Grant 2014). 
 
Keywords: core outcomes, postpartum haemorrhage, PPH, pregnancy, Delphi 
 
Tweetable abstract: Core outcome sets for PPH:  9 core outcomes for PPH prevention and 12 core 
outcomes for PPH treatment. 
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INTRODUCTION 
 
Over 250,000 women die each year from complications of childbirth.1 PPH is the leading cause of maternal 
mortality worldwide.2 It is usually defined as blood loss of 500 ml or more from the genital tract within 24 
hours after childbirth.  
 
Interventions for PPH have been evaluated in a large number of studies. However evidence is difficult to 
interpret and compare across studies due to variations in the outcomes measured by researchers. In a study 
looking at outcomes reported in PPH trials published between 1997 and 2015, 121 trials for prevention of 
PPH used 68 different primary outcomes.3 The most commonly reported outcome was assessment of blood 
loss, with more than ten different cut-offs specified at times ranging from 30 minutes to 48 hours. There 
were little data on short and long-term morbidity or mortality, and few patient reported outcomes.  
 
Reduction in maternal mortality is part of the Sustainable Development Goals set by the United Nations.1 
One strategy for achieving this is to ensure that the most effective evidence based therapies are used to 
manage PPH, and global standards follow evidence based guidelines.1 Recommendations can only be 
robust if they are based on good quality evidence, where interventions are compared using indicators that 
are standardized and are important measures of wellbeing.  
 
The aim of this project was to develop consensus among international stakeholders on a set of core 
outcomes that should be used in trials and systematic reviews to evaluate (1) preventative interventions and 
(2) therapeutic interventions for women with PPH. A secondary aim was to provide guidance on how to 
report these core outcomes. 
  
METHODS 
 
The project was registered prospectively with the Core Outcome Measures in Effectiveness Trials 
(COMET) initiative4 and funded by the British Medical Association (BMA). The protocol was peer-
reviewed by the COMET team and funding body. Ethics approval was not required.5 The manuscript has 
been reported in line with the COS-STAR guidelines for COS reporting.6 Methods are summarised in 
Figure S1 and further details are available in Appendix S1. 
 
The Steering Committee included two obstetricians (SM, ZA), a midwife (AC) and two 
methodologists/statisticians with expertise in development of COS (JK, PW). A Scientific Advisory Group 
(SAG) was set up to provide multidisciplinary expert input and an international perspective (16 members 
from 10 countries and seven stakeholder groups; Appendix S1). Seven stakeholder groups were agreed a 
priori to be relevant to the project (obstetricians, midwives, anaesthetists, haematologists, neonatologists, 
health strategists/methodologists and women’s representatives).  
 
 
 4 
1. Identification of participants for the Delphi Survey 
Our aim was to involve as many participants as possible, with a minimum of 10 in each stakeholder group 
to allow numbers to be meaningful taking into account possible attrition in Round 2.8 The same 
participants were asked to take both the prevention and treatment PPH surveys. Participants were identified 
from published trial reports and Cochrane reviews on PPH. Invitations were also sent through the CoRe 
Outcomes in Women’s and Newborn health (CROWN) Initiative journal editors mailing list.9 Women’s 
representatives were invited through the National Childbirth Trust parent support group (UK) and personal 
contacts. Further invitations to stakeholders were sent out by snowballing with suggestions from the SAG, 
authors contacted and targeted participants. The SAG also took a modified Delphi survey separately. This 
was a methodological investigation to assess the impact of group size and number of panels on selection of 
outcomes for a COS, and will be the subject of a separate paper.  
 
2. Identification of outcomes 
To identify outcomes relevant to PPH, two systematic reviews of randomized trials were undertaken - one 
evaluating interventions for prevention of PPH (NA and ZA), the other, treatment of PPH (SM and ZA) 
(details in Appendix S1). All published outcomes were considered for inclusion in the COS. .  
The reviews identified 121 randomised trials with 160 different outcomes for prevention of PPH and 16 
RCTs with 95 different outcomes for treatment of PPH. Outcomes were classified under overarching 
domains (blood loss assessment, mortality and morbidity, use of additional interventions and resources, 
women’s and clinicians’ views, adverse outcomes, and neonatal outcomes). Duplicate outcomes were 
removed, similar outcomes combined and variations in methods of reporting each outcome noted (Tables 
S1 and S2). Two outcomes - women’s and healthcare professionals’ views, were added by the Steering 
Committee. A total of 35 outcomes for prevention of PPH and 31 outcomes for treatment of PPH were 
entered into Round 1 of the Delphi.  
 
3. Delphi Survey 
A two-round, anonymised electronic Delphi survey was designed on DelphiManager10 to obtain consensus 
on the importance of each outcome among stakeholders. It was decided a priori that results of the Delphi 
would be used to inform the face-to-face stakeholder meeting where a final COS would be agreed.  
 
Each outcome was listed in the survey with its plain language summary.  Participants were asked to rate 
the importance of each outcome between 1 and 9 on a Likert scale, with 1-3 being ‘not important’, 3-6 
‘important but not critical’ and 7-9 being ‘critically important’ to report in trials, or select unable to 
comment. This scale is recommended by the Grading of Recommendations Assessment, Development and 
Evaluation working group.12 Participants were invited to suggest additional outcomes for consideration for 
the COS in Round 1 using free-text responses.  
 
Potential participants were invited to register for the study via email, and the Delphi survey was emailed to 
those who registered. The closing date was set 4 weeks after each round and an e-mail reminder was sent 
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on days 14, 21, and 28. Non-responders in Round 1 were not invited to participate in Round 2. Non-
responders in Round 2 were sent additional emails to improve response rate. 
 
In Round 2, participants were able to view anonymised results from the first round, presented as the 
distribution of scores for each outcome in each stakeholder group separately. This allowed participants to 
reflect on their choices prior to completing the second round of the survey. Additional relevant outcomes 
suggested by participants in Round 1 were added to Round 2 (16 for prevention and 18 for treatment) 
(Figures S2 and S3).  
 
We defined consensus for the Delphi a priori based on guidance in The COMET Handbook.8 For inclusion 
in the COS, outcomes required at least 70% of participants in each stakeholder group to score the outcome 
as critically important and less than 15% to score the outcome as not important. Outcomes excluded from 
the COS required at least 70% of participants in each stakeholder group to score the outcome as not 
important and less than 15% to score the outcome as “critical.”  If outcomes did not meet either criterion 
they were classified as outcomes with no consensus. 
 
4. Face-to-face meeting 
The final phase of the project was a face-to-face consensus meeting (Liverpool, United Kingdom 16-17th 
August 2016). Twenty-five people attended the meeting, and each stakeholder group was represented: five 
obstetricians, three midwives, four women’s representatives, five health strategist/methodologists, one 
anaesthetist, one haematologist, and one neonatologist (Appendix S1). Findings of the survey were 
presented and participants were given an opportunity to discuss each outcome. Consideration was given as 
to whether the outcome was relevant in all setting and for all women recruited. Outcomes could be re-
named or reconfigured if there was full consensus at the meeting to do so. Participants then scored each 
outcome between 1 and 9 on the Likert scale, for inclusion or exclusion in the COS with an anonymous 
voting system using electronic keypads. Consensus at the meeting required a majority of 70% of 
participants to score the outcome as critically important (7-9) to include in the COS.  
 
5. Methodology for how to report outcomes 
Consensus on how to report the COS outcomes was developed on Day 2 of the meeting by an Expert 
Committee (n=20; Appendix S1). The aim was not to create new definitions but to select a preferred 
method of reporting the outcome among existing methods in published literature where possible and to 
make research recommendations where this was not possible.  
 
We used recommended standards on how to report summary results for trial reporting13  and considered the 
specific metric on how to measure the outcome, the method of data aggregation (continuous or categorical) 
and the time frame in which to measure the outcome.. Variations in outcome reporting were presented and 
expert presentations delivered. Options were discussed, and scored. Consensus was defined a priori as 
more than 70% of participants voting for a preferred option of reporting, and majority view was defined as 
more than 50% of participants preferring one option from among the top three options, thereby indicating 
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the strength of the recommendation.  
 
RESULTS 
 
Survey participants came from 36 different countries (Figure S4), and represented all seven stakeholder 
groups. For Round 1 of the Delphi, 205 participants responded to the prevention of PPH survey and 197 to 
the treatment survey. Round 2 was completed by 74% (152/205) and 73% (143/197) of participants 
respectively (Table 1).   Overall, 77% of those who took the survey had exposure to PPH either through 
personal experience or through caring for women who had experienced PPH. Among women’s 
representatives, 41% had experienced a PPH. 
 
Assessment of outcomes for the prevention and treatment of PPH COS is shown in Figure 1.  Delphi 
consensus was reached for including five outcomes in the COS for prevention of PPH and ten outcomes in 
the COS for treatment of PPH. No outcomes fulfilled criteria for exclusion. There was no consensus on the 
remaining outcomes. After discussing these results at the face-to face meeting, the final COS included nine 
outcomes for prevention and 12 outcomes for treatment of PPH. At least one outcome from each domain 
was included in both COS, and there was significant overlap in outcomes included between the two COS. 
 
1. PPH Prevention COS 
For the evaluation of interventions for prevention of PPH, the final COS outcomes are presented in Table 
2. At the stakeholder meeting, all outcomes that met the Delphi consensus criteria were included in the 
COS except for hysterectomy. Although stakeholders at the meeting agreed that hysterectomy was an 
important outcome, it was not felt to be critically important in the context of trials for PPH prevention 
because it is a very rare event. Although rare but critically important outcomes are also important to 
include in a COS, and such an outcome of maternal mortality has been included, there was consensus that 
the PPH prevention COS would be more informative if it captured other measures of maternal morbidity 
for which data were more likely to be available from trials rather than having a COS with little data 
available for multiple outcomes. Blood loss was thought to be an important outcome for PPH trials to 
report, although difficulties in assessing it were acknowledged. Four additional outcomes were included in 
the PPH prevention COS subsequent to stakeholder discussions and voting. Two of these outcomes, ‘use of 
blood transfusion’ and ‘use of additional uterotonics’ were borderline for inclusion in the Delphi survey 
(Table 2). The outcomes ‘transfer to ITU’ and ‘transfer to a higher facility’ in the Delphi were 
reconfigured at the stakeholder meeting to ‘transfer to a higher level of care’ to capture data on an 
escalation in the level of care required for the woman, which, it was recognized, would depend on the 
initial setting of the woman. There was also consensus among stakeholders at the meeting that patient 
reported outcomes, although not included in the Delphi consensus, were important to include in the COS, 
and this was strongly advocated by the women’s representatives. It was felt that these should capture a 
woman’s sense of wellbeing, as well as acceptability and satisfaction with the intervention. Among 
outcomes in the neonatal domain, there was consensus that breastfeeding would be an important outcome 
as a PPH may impact on a woman’s wellness and ability to establish or maintain breastfeeding if she 
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intended to breastfeed, or there could be a potential impact of the intervention on breast milk itself. 
 
2. PPH Treatment COS 
For the evaluation of interventions for treatment of PPH, the final COS is presented in Table 3. Nine of the 
10 outcomes that met the Delphi consensus criteria were included in the final COS.. Two very similar 
outcomes - ‘shock’ and ‘maternal resuscitation due to shock’ - were both included by the Delphi survey. 
Hence, consensus at the stakeholder meeting was to include ‘shock’ only in preference to ‘maternal 
resuscitation due to shock’ as the latter would be more complex to measure. The outcome disseminated 
intravascular coagulation, (DIC) was renamed as coagulopathy based on recommendations by 
haematologists because coagulopathy is the more accurate term; DIC does not have a validated definition 
in PPH and constitutes only a small subset of coagulopathies associated with PPH. Multiple organ failure 
was renamed as ‘any organ dysfunction’, in line with the World Health Organization’s recommendations 
on how to capture severe pregnancy complications including organ dysfunction in the WHO near-miss 
approach for maternal health.14 A number of outcomes in the Delphi survey aimed at capturing failure of 
initial treatment, such as use of additional medical or advanced surgical interventions such as balloon 
insertion or uterine artery embolisation or ligation. However, at the meeting it was recognized that type of 
escalation of therapy would depend on the trial intervention itself – medical or surgical. Therefore, these 
outcomes were reconfigured into the outcome ‘Use of any additional haemostatic intervention’ to capture 
failure of the trial intervention itself, as this would be applicable to all trials, regardless of the intervention 
they were evaluating.  The other outcomes added were a woman’s sense of wellbeing and acceptability and 
satisfaction with the intervention, and breastfeeding as specified above in the prevention of PPH COS.  
 
3. How to report COS outcomes 
The Expert Committee Recommendations on how to report the COS outcomes are presented in Table 4, 
along with explanations.  Most recommendations were agreed by consensus. Those agreed by majority 
view included reporting of hysterectomies specifically carried out to stop PPH, to avoid confounding data 
with hysterectomies carried out prophylactically or for other indications. For time frames for measuring 
outcomes, there was consensus that in the context of randomised trials outcome data should be collected 
from the point of randomisation. The time limit up to which outcomes should be measured was left to 
trialists for most outcomes to accommodate for local protocols and resource availability. However a 
majority view recommendation was put forward for blood loss to be assessed (measured or estimated) up 
to cessation of active bleeding, as this is an area where standardization is particularly lacking and time 
frame selection is likely to impact on data significantly. For hysterectomy, the majority recommendation 
was to report it at least up to hospital discharge as most hysterectomies are likely to occur by that time in 
the context of PPH. 
 
For the patient reported outcomes and breastfeeding, it was felt by the stakeholder groups that further work 
was needed to develop tools to capture what aspects of these outcomes were most important to women in 
the context of a PPH. 
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DISCUSSION 
 
Main findings 
Consensus on PPH COS was developed among an international panel of stakeholders through a Delphi 
survey and face-to-face meeting. For the evaluation of interventions for prevention of PPH, nine core 
outcomes were selected and for treatment of PPH, 12 core outcomes. Expert committee recommendations 
where developed on how to report each outcome where possible, and a research agenda was set for two 
outcomes where this was not possible.  
  
Strengths and Limitations 
This project has several strengths.  Firstly, the methodology was defined a priori based on guidelines by the 
COMET Initiative.8 The Delphi exercise has the advantage of including views of a larger number of 
geographically distant participants. Participants in the Delphi were still able to consider the views of other 
stakeholder groups in Round 2, to reconsider their opinion without being overly influenced by domineering 
individuals. Results were further refined at the face-to-face meeting which allowed for rich discussions as 
well as the ability to debate and persuade others. Secondly, stakeholders came from a range of relevant 
specialties. Importantly, consumer representatives, who are sometimes overlooked in similar projects,25-26 
were included at all stages of the process. There was representation from both those who had and had not 
experienced PPH. Our parent representatives impacted the final COS outcomes by influencing other 
stakeholders at the face-to-face meeting to include patient reported outcomes. Thirdly, there was 
representation from a wide range of countries of variable income status in the Delphi and at the face-to-
face meeting, so that the COS developed would be applicable across different settings. Fourthly, we have 
developed COS for both prevention and treatment of PPH to cover the full spectrum of PPH intervention 
trials. It is not surprising that there is significant overlap in outcomes selected for the two COS. However 
the PPH treatment COS appropriately includes more outcomes that capture significant maternal morbidity 
in the presence of an established PPH. And finally, a COS often tells researchers what outcomes to use, but 
not how to report them, making it difficult to achieve adequate standardisation; we have developed Expert 
Committee Recommendations on how to report the outcomes selected for PPH COS to provide better 
guidance to researchers.  
 
The limitations of this project are that outcomes were obtained largely from systematic reviews and 
participants in the Delphi exercise; we did not conduct formal interviews with women. Secondly, we asked 
participants to identify one key stakeholder group to which they belonged. Some participants may have 
belonged to more than one stakeholder group and this may have influenced how they scored outcomes, but 
data are not available to explore this further. Thirdly, representation from each stakeholder groups was not 
equal; this may have impacted on the outcomes selected. Finally, although we have developed guidance on 
how to report COS outcomes, these recommendations are from a small group of experts, and have not been 
subjected to the same rigorous Delphi process in a large group. However, it is debatable whether a Delphi 
process is the optimum method for developing consensus on how to report outcomes. More complex 
discussions may need to be undertaken for consensus on measurement instruments by stakeholders who 
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may be different from those partaking in the ‘what to measure’ Delphi. Generic methodological guidelines 
on how to select standardised instrument measures for outcomes have recently been published.27 They 
recommend identifying all possible measurement instruments for an outcome, and selecting one with high 
quality of evidence for good validity and internal consistency, that is feasible to measure in the target 
population. These guidelines have not yet been applied prospectively for COS in maternal health. Our 
systematic reviews identified the different ways in which COS outcomes have been reported, and the 
feasibility of applying the instruments in an international setting was considered when making 
recommendations on how to report outcomes. While validity may be excellent for the more objective 
outcomes included in the COS, such as units of blood transfusion or maternal death, measurement tools for 
other outcomes such as blood loss are well known for their poor accuracy.   
 
Interpretation 
To our knowledge, there is no other published COS for PPH. These COS include outcomes that capture 
meaningful morbidity (shock, hysterectomy, organ dysfunction) and mortality. They also include outcomes 
with high event rates upon which sample size calculations could be based for smaller studies (blood loss, 
use of additional uterotonics or blood transfusion).  Resource use may be assessed through use of 
additional interventions and level of care such as ITU use. Patient reported outcomes (wellbeing and 
satisfaction) and breastfeeding are also captured but require further qualitative research on how best to 
measure these outcomes. Until further data are available, we would encourage researchers to clearly report 
the measures they have used. 
 
Although these outcomes aim to assess the impact of interventions evaluated on severity of PPH, some 
outcomes may be influenced by local practices. For example, thresholds used for transfusing blood or 
transferring a woman for higher level of care may vary across trial settings and studies. For such outcomes 
we would encourage authors to interpret results bearing the potential impact of local practices in mind. 
 
We would recommend researchers evaluating interventions for PPH to report these COS outcomes as a 
minimum, along with any other outcomes of interest to their study. Where these COS are not reported, 
researchers are encouraged to provide an explanation, for transparency and to reduce the risk of reporting 
bias. Future trials evaluating interventions for PPH should report any barriers identified to data collection 
for these COS outcomes. COS may be updated to provide guidance in response to such feedback.  
 
CONCLUSIONS 
The PPH COS, developed through an international multidisciplinary effort, will help standardise outcome 
reporting in this area, and facilitate comparison of data across studies, to guide clinical practice. We 
recommend that researchers evaluating interventions for PPH prevention and treatment should report these 
COS outcomes as a minimum, along with any other outcomes of interest. Further work is needed on how to 
best to report women’s sense of wellbeing, acceptability and satisfaction with the intervention and 
breastfeeding in the context of PPH.  
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Appendix S1. Additional methods  
 
1. Scientific Advisory Group (SAG) 
SAG members were invited to participate based on their expertise in PPH or their own specialty, and were 
identified through previous involvement in international projects and publications or recommendations of 
experts. International representation from high, middle and low income countries was taken into 
consideration.7 At least one person from each stakeholder group was invited to join the SAG. Members 
included four obstetricians (EA, NA, BF, AW), three midwives (DD, KG, CH), three health strategists (JB, 
MG, JS), two anaesthetists (ASDB, ShuM), two women’s representatives (GG, AB), one haematologist 
(PC), and one neonatologist (ZAB). All members are co-authors of this report. 
 
The SAG was also asked to take Round 1 of the Delphi survey separately, followed by a teleconference 
and then Round 2 on a limited number of outcomes that SAG members felt needed to be scored again after 
discussion. This was done as a methodological investigation to assess whether a small group of 
representative experts in a single multidisciplinary panel would select the same outcomes for a COS as a 
larger group of Delphi participants in multiple panels. Results of this investigation will be the subject of a 
separate paper. For PPH COS development, the SAG survey results were also presented at the face-to-face 
meeting as a separate stakeholder group. 
 
2. Identification of outcomes 
 
Methods for systematic reviews for prevention and treatment of PPH 
 
Aim 
To identify all outcomes reported in published RCTs evaluating interventions for  
1. prevention of PPH 
2. treatment of PPH 
 
Inclusion Criteria 
1. Types of studies: RCTs  
2. Types of participants: women delivering at any gestation, regardless of risk of PPH were included. 
For prevention trials, women were included if they were pregnant or in the postnatal period, and for 
treatment trials postnatal women were included.  
3. Types of interventions: We included all types of interventions given primarily for preventing PPH for 
the prevention review or treating primary PPH for the treatment review.  
4. Types of outcomes: All published outcomes were included. 
 
Search strategy 
 
For the PPH prevention review, searches were conducted from January 1997, after publication of the first 
CONSORT statement, to December 2012. We searched the Cochrane Central of Controlled Trials 
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(CENTRAL), Embase, Medline, Web of knowledge and Scopus, for relevant RCTs using keywords and 
MeSH terms “postpartum hemorrhage, labour stage, third, ergovovine, misoprostol, medicine, Chinese 
traditional, Uterus and massage, carboprost, tranaxemic acid, umbilical cord and uterus and pressuet”.  
 
For the PPH treatment trials, searches were conducted from January 1997 until January 2015. We searched 
the Cochrane Pregnancy and Childbirth Group’s (PCG) Specialised Register for randomised trials relevant 
to PPH. The register is a database of citations to published and unpublished controlled clinical trials in 
perinatal medicine. It contains over 17,000 records, with an annual accrual of 1000 new records.9 The 
register is maintained by monthly searches of CENTRAL; weekly searches of MEDLINE and EMBASE; 
handsearches of 30 journals and the proceedings of major conferences; and weekly current awareness alerts 
for a further 44 journals plus monthly BioMed Central email alerts. In addition, members of the Cochrane 
Collaboration contribute to the register from all around the world by sending in reports of RCTs retrieved 
through sources including local foreign language databases and personal communications. Details of the 
PCG search strategy can be found on 
http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/PREG/frame.html. RCTs for this study were 
retrieved using the register’s codes for PPH treatment. 
 
No language restrictions were applied. Titles and abstracts were screened and full papers for potentially 
eligible studies were retrieved. Studies were assessed for inclusion by two people independently (NA and 
ZA for prevention trials and SM and ZA for treatment trials) using the pre-specified criteria outlined in the 
methods section above. Any disagreements were resolved by discussion.  
 
Data Extraction and Analysis 
Data were collected on all reported outcomes from full papers of each publication on a pre-defined data 
extraction form. Data were entered into a Microsoft Excel database, double checked for accuracy, and 
analysed using Microsoft Excel. 
 
Results 
For the outcomes obtained from systematic reviews (n=160 for prevention and n=95 for treatment), 
clinicians in the Steering Committee (SM, ZA, AC) classified each outcome under overarching domains, to 
make them easier to present and interpret. Domains were developed to capture different themes across care 
of women with PPH, including blood loss assessment, mortality and morbidity, use of additional 
interventions and resources, women’s and clinicians’ views, adverse outcomes, and neonatal outcomes.  
 
3. Delphi Survey 
Plain language summaries were created for each outcome with input from a women’s representative (GG) 
to clarify what each outcome meant. The readability score11 was kept at 16. The survey was piloted by the 
steering committee. Minor changes were made in the survey structure.  
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Two email invitations were sent to all potential participants, one week apart to participate in the study. The 
email included a link that allowed them to register for the study. Personalised reminders were sent to 
maximise participation.  
New outcomes suggested by participants in Round 1 were assessed for inclusion by the Steering 
Committee and SAG. Relevant outcomes were added to Round 2 (16 for prevention and 18 for treatment) 
(Figure S1 and Figure S2). Hence participants scored 51 outcomes for inclusion in the PPH prevention 
COS and 49 for the treatment COS in Round 2 of the Delphi and at the face-to-face meeting. Results were 
analysed on Microsoft Excel. 
 
4. Face-to-face meeting 
Invitations for the face-to-face meeting were based on 1) representation from each stakeholder group 2) 
international representation from high and low income countries 3) expertise in PPH and 4) feasibility of 
travel within funding available. Twenty-five people attended the meeting, including an independent chair 
and steering group members facilitating the meeting (n=4). Participants scoring outcomes (n=20) also 
included SAG members (n=14). Each stakeholder group was represented: five obstetricians, three 
midwives, four women’s representatives, five health strategist/methodologists, one anaesthetist, one 
haematologist, and one neonatologist.  
 
Information material including Delphi results was sent to participants before the meeting. At the meeting, 
procedures and consensus criteria (defined a priori) were explained. Findings of the survey were presented 
for prevention and treatment of PPH separately, with discussion and agreement of the final COS for 
prevention in the first half of the day, and for treatment in the second half. For each outcome, the score 
distribution and overall score were presented by stakeholder group.  
 
5. Methodology for how to report outcomes 
The Expert Committee consisted of an independent chair and two steering committee members (SM, AC) 
to facilitate the meeting, and 17 voting participants: three obstetricians (AW, BF, EA), three midwives 
(DD, CH, KG), two anaesthetist (ASB, SM), one haematologist (BH), three health strategists (JB, JS, JPS), 
one methodologist (HS), two statisticians (JK, SL) and two women’s representatives (GG, AB).  
 
Variations in the reporting of each included outcome were presented, based on data collected from the 
systematic reviews. Expert presentations were delivered on blood loss assessment, blood transfusion, 
assessment of shock/shock index, hysterectomy, and maternal death. Options were discussed, and scored 
using anonymised electronic touchpads. It was decided a priori that a research agenda would be developed 
where it was not possible to agree how to report an outcome or where further work was needed before 
guidance could be given. 
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Table 1. Participants in Delphi survey by stakeholder group 
 
 
 Prevention of PPH COS Treatment of PPH COS 
 
Stakeholder group Round 1 
n = 205  (%) 
Round 2 
n = 152 (%) 
Round 1 
n = 197 (%) 
Round 2 
n = 143 (%) 
Anaesthetists 14 (7) 11 (7) 14 (7) 11 (8) 
Haematologists 10 (5) 8 (5) 10 (5) 8 (6) 
Midwives 28 (14) 21 (14) 27 (14) 21 (15) 
Neonatologists 10 (5) 9 (6) 10 (5) 9 (6) 
Obstetricians 92 (45) 62 (41) 88 (45) 58 (41) 
Health strategists 21 (10) 19 (13) 20 (10) 15 (10) 
WoŵeŶ’s 
representatives 
30 (15) 22 (14) 28 (14) 21 (15) 
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Table 2. Prevention of PPH Core Outcome Set 
 
 
Domain Outcome 
 
% Consensus 
at Meeting* 
(n=20) 
Consensus in Delphi Round 2** 
 
A
n
a
e
st
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e
ti
st
s 
n
=
1
1
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a
e
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a
to
lo
g
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ts
 
n
=
8
 
M
id
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e
s 
  
  
n
=
2
1
 
N
e
o
n
a
to
lo
g
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t 
n
=
9
 
O
b
st
e
tr
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n
s 
n
=
6
2
 
P
a
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n
t 
R
e
p
s 
n
=
2
2
 
P
o
lic
y
 M
a
k
e
rs
 
n
=
1
9
 
S
A
G
  
  
  
 
n
=
1
6
 
Blood loss 
assessment 
1. Blood loss after birth 95% 
91% 88% 95% 89% 89% 95% 79% 81% 
Morbidity / 
Mortality 
2. Shock 74% 
 
100% 75% 95% 100% 97% 100% 94% 81% 
3. Maternal death 100% 
 
100% 88% 100% 100% 98% 95% 100% 100% 
Use of additional 
interventions 
4. Blood transfusion (RBC) 84% 
 
100% 100% 81% 67% 97% 86% 82% 94% 
5. Use of additional uterotonics 90% 
 
91% 86% 95% 78% 85% 76% 67% 94% 
Use of resources 6. Transfer to higher level of care 79% 
 
 
Reconfigured 
Parent reported  
outcomes 
 
7. a) WoŵeŶ’s seŶse of ǁellďeiŶg  
     
    ď) WoŵeŶ’s aĐĐeptaďility of aŶd 
        satisfaction with intervention  
a) 79% 
 
82% 88% 86% 56% 69% 95% 31% 81% 
b) 79% 
 
45% 50% 43% 11% 49% 81% 44% 69% 
Neonatal 
outcomes 
8. Breastfeeding 79% 
9% 13% 33% 22% 9% 52% 40% 56% 
Adverse effects 9. Adverse effects of intervention 
for mother (and baby if relevant) 
79% 
100% 88% 95% 78% 81% 90% 94% 94% 
*% of participants voting outcome as critically important at Stakeholder Meeting; **% participants voting outcome as critically important among 
different stakeholder groups in Delphi.  
  
 20 
Table 3. Treatment of PPH Core Outcome Set  
 
 
Domain Outcome % Consensus 
at Meeting* 
(n=20) 
Consensus in Delphi Round 2** 
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s 
n
=
1
1
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ts
 
n
=
8
 
M
id
w
iv
e
s 
  
  
 
n
=
2
1
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n
=
9
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s 
n
=
5
8
 
P
a
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n
t 
R
e
p
s 
 
n
=
2
1
 
P
o
lic
y
 M
a
k
e
rs
 
n
=
1
5
 
S
A
G
  
  
  
 
n
=
1
6
 
Blood loss 
assessment 
1. Blood loss  90% 
100%
 
100%
 
90%
 
78%
 
88%
 
81%
 
80%
 
79% 
Morbidity / 
Mortality 
2. Shock 95% 
 
90%
 
86%
 
85%
 
89%
 
84%
 
95%
 
80%
 
81%
 
3. Coagulopathy 74% 
 
100%
 
88%
 
95%
 
100%
 
96%
 
100%
 
93%
 
88%
 
4. Hysterectomy 90% 
 
90%
 
100%
 
100%
 
100%
 
100%
 
90%
 
93%
 
94%
 
5. Any organ dysfunction 95% 
 
100%
 
100%
 
100%
 
89%
 
96%
 
100%
 
93%
 
81%
 
6. Maternal death 100% 
 
100%
 
100%
 
100%
 
100%
 
98%
 
95%
 
100%
 
100%
 
Use of 
additional 
interventions 
7. Blood transfusion  a) RBC    
                                         b) blood       
                                              products 
a) 95% 
 
100%
 
100%
 
95%
 
89%
 
96%
 
100%
 
93%
 
100%
 
b) 74% 
 
100%
 
100%
 
95%
 
78%
 
91%
 
95%
 
79%
 
88%
 
8. Use of any additional haemostatic  
    intervention 
90%  
Reconfigured 
Use of 
resources 
9. Transfer to higher level of care 82%  
Reconfigured 
atient reported 
outcomes 
ϭϬ. a) WoŵeŶ’s seŶse of wellďeiŶg  
       ď) WoŵeŶ’s aĐĐeptaďility of aŶd  
           satisfaction with intervention  
a) 84% 
 
64%
 
71%
 
61%
 
38%
 
62%
 
75%
 
40%
 
57%
 
b) 82% 
55%
 
38%
 
65%
 
22%
 
46%
 
76%
 
53%
 
81%
 
Neonatal 
outcomes 
11. Breastfeeding 82% 
18%
 
0%
 
35%
 
44%
 
18%
 
43%
 
40%
 
50%
 
Adverse 
effects 
12. Adverse effects of intervention 
     on mother (and baby if relevant) 
94% 
73%
 
63%
 
75%
 
56%
 
53%
 
71%
 
27%
 
75%
 
*% of participants voting outcome as critically important at Stakeholder Meeting; **% participants voting outcome as critically 
important among different stakeholder groups in Delphi. 
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Table 4. PPH Core Outcome Sets: how to report outcomes  
Outcome COS 
 
Expert Committee Recommendations Comments and Explanations 
1. Blood loss  Prevention Number of women with ≥5ϬϬ ŵls AND ≥ϭϬϬϬ ŵls blood loss AND median or mean* 
blood loss in each group, measured or estimated
§
 from birth of baby, up to 
cessation of active bleeding
§
. 
It was not possible to make recommendations on the method that should be 
used for blood loss assessment. Evidence is contradictory on whether 
outcomes are impacted by different methods used (blood loss measured or 
estimated).15-17 A review on this topic is currently underway.18 Trialists will 
also need to consider what methods are feasible based on their trial setting. Treatment Median or mean* blood loss in each group, measured or estimated as additional 
blood loss after the intervention, up to cessation of active bleeding
§
. 
2. Shock Prevention  
& Treatment 
Number of women with shock in each group, based on clinical assessment as 
defined by trialists. 
Various methods have been used to assess shock and there is growing 
evidence on use of shock index in obstetric patients.14,19-23 Evidence from 
prospective studies is awaited before recommendations can be made on 
how to best assess shock.24  
3. Maternal death Prevention 
& Treatment 
Number of maternal deaths in each group from all causes and maternal deaths 
from PPH, from randomisation up to time decided by trialists.
§
 
Maternal death, as defined by the World Health Organization.14 
4. Blood transfusion Prevention 
& Treatment 
Number of women with any RBC blood transfusion in each group AND mean or 
median* RBC units transfused in each group from randomisation up to time 
decided by trialists. For treatment COS only, number of women with any other 
blood products in each group should also be reported. 
RBC blood transfusion may also include cell salvage. Other blood products 
include platelets, fresh frozen plasma, and cryoprecipitate. 
5. Transfer to higher level  
    of care 
Prevention 
& Treatment 
Number of women transferred to a higher level of care in each group from 
randomisation up to time decided by trialists. 
A higher level of care may include transfer to hospital, higher facility, 
intensive care unit or specialist ward depending on trial setting.   
6. Use of additional   
haemostatic intervention 
Prevention Number of women in whom any additional uterotonics were used in each group 
from randomisation up to time decided by trialists. 
The additional haemostatic intervention will depend on what the trial 
intervention is. This may include additional uterotonics in trials evaluating 
medical treatments or surgical methods in trials evaluating more invasive 
methods such as balloon tamponade. The aim of this outcome is to capture 
failure of the trial intervention, and need for use of other treatments. 
Treatment  Number of women in whom any additional haemostatic intervention (medical or 
surgical) was used in each group from randomisation up to time decided by 
trialists. 
7. Hysterectomy Treatment Number of women who had a hysterectomy to stop bleeding in each group, from 
randomisation, at least up to hospital discharge. 
Hysterectomies done specifically to stop bleeding should be reported to 
avoid confounding data with hysterectomies done prophylactically or for 
other indications. 
8. Coagulopathy Treatment Number of women with coagulopathy in each group from randomisation up to 
time decided by trialists. 
Coagulopathy should be defined as specified in annex 1 of the document 
WHO near miss approach for maternal health.14 
9. Organ dysfunction Treatment Number of women with any organ dysfunction in each group 
 
from randomisation 
up to time decided by trialists. 
Organ dysfunction should be defined as specified in the document WHO 
near-miss approach for maternal health.
14
 
10. Adverse effects Prevention  
& Treatment 
Number of women (and babies if relevant) with side effects and serious adverse 
effects in each group.   
Side effects and serious adverse effects will be intervention specific, 
therefore should be defined by trialists as appropriate. 
11. Breastfeeding  Prevention  
& Treatment 
There is a need to explore in future research studies how to best report this 
outcome. 
Aspects considered important were initiation and maintenance of 
breastfeeding. 
12. Patient reported    
      outcomes 
Prevention  
& Treatment 
There is a need to explore in future research studies how to best report these 
outcomes. 
OutĐoŵes that Ŷeed ƋualifiĐatioŶ aƌe a ǁoŵaŶ’s seŶse of ǁellďeiŶg, 
acceptability and satisfaction with the intervention. Further research is 
ƌeƋuiƌed ǁith ǁoŵeŶ’s ǀieǁs oŶ hoǁ to ďest ƌepoƌt these. 
*Report mean or median depending on data distribution; §agreed by majority view rather than consensus 
